Vivus Pharmaceuticals is having an absolutely awful day, with the stock down more than 13% after the company reported its Q4 results. The launch of its first-in-class obesity drug Qsymia was very highly anticipated among investors with the market potential being huge in this space, but sales just aren't panning out that way. The other major competitor in this space is a drug called Belviq from Arena Pharmaceuticals , which was also highly anticipated and also disappointed in sales, though sales are better than Qsymia, despite being prescribed roughly half as frequently.
In this video, Motley Fool health-care analyst David Williamson points to Vivus' marketing tactics as one big problem for its sales. The company is offering Qsymia at a discount, with free initial doses followed by doses at $75 per month for up to 3 months. The percentage of free scripts were 23% total. David also looks at why management's suggestion that the poor sales are a seasonal problem doesn't make sense, and looks ahead to one other potential candidate that may finally win the war in the obesity space.
Biotechs make investors rich, but they also make investors nervous.
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In The Motley Fool's brand-new free report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.
The article Another Big Failure for VIVUS, Inc. originally appeared on Fool.com.David Williamson and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.